Evaluating the effects of Prostatan as an adjunct drug in treatment of Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia (BPH) is the most common benign tumor in men. Due to the side effects of chemical drugs, phytotherapy has become a treatment method in BPH since 1990s. Prostatan is a plant extract widely available in Iran. In this study, we evaluated the therapeutic effects of Prostatan drop in combination with Prazosin in alleviating BPH symptoms. In a single blind randomized clinical trial, 66 men over 50 years with BPH symptoms who were visited in Vali-e-Asr hospital of Arak were randomly divided in two groups and treated with either Prostatan (40 drop,TDS) plus Prazosin (1mg, BD)or Prazosin (1mg, BD)alone. AUA symptom score, PSA (prostate-specific antigen) levels, Prostate volume, post voidal residue (PVR) by sonograms and uroflowmetry results were determined before and 12 weeks after treatment. Data was analyzed by T and Man- Whithey u tests. Before treatment there were no significant differences in age, PSA, PVR, AUA symptom score, Prostate volume and uroflowmetry between the two groups. After treatment the mean of PSA levels, Prostate volume and PVR did not differ between the two groups. In the Prostatan plus Prazosin group, the mean of AUA symptom score was 3.3 less (p<0.0001) and the mean of maximal urine flow rate was 2.7 ml/s more than the Prazosin group (p<0.0001). Regarding results, it seems that adding Prostatan to Prazosin against Prazosin alone enhances its effects on controlling BPH symptoms and increases urine flow rates.